Reviewing the Global Medicinal Chemistry and GPCR Summit
Posted 29th January 2018 by Jane Williams
MedChemNet and Future Medicinal Chemistry were thrilled to attend the Global Medicinal Chemistry and GPCR Summit, organised by Global Engage. The event shared the latest in medicinal chemistry and GPCR developments with delegates from across the globe. Represented at the summit were a number of large and small pharmaceutical companies, as well as biotechnology companies, CROs and academics.
Big Data Analytics and Artificial Intelligence: 7 Design Principles to Empower Life Science Researchers
Posted 5th January 2018 by Jane Williams
Life sciences research is increasingly relying on big data analytics to drive scientific discovery. One of the contributing factors to this trend is the fact that researchers are confronted with a rapidly growing body of scientific literature and databases required to interpret experimental outcomes.
Staying Ahead of Life Sciences Research and Implementation Trends in 2017 and Beyond
Posted 22nd December 2017 by Jane Williams
The traditional product pipeline, which information technology will compress and alter significantly in the life sciences in the coming years. Source: Wikimedia user MattBishop5 (CC BY-SA 3.0).
This article was originally published by Dassault Systèmes BIOVIA in October 2017, and is published here with permission.
Where can life science companies go operationally to maintain or create a competitive advantage? This question has been a constant in the industry since its inception, but recent advances in older technologies like Laboratory Information Management Systems (LIMS) and the appearance of promising newer technologies like the Internet of Things (IoT) have changed the nature of the answer. Which new technologies that are theoretically worthwhile have matured enough to be gracefully implemented operationally?
Big Data, Informatics and Pharma: An Open Letter From Vaibhav Narayan
Posted 24th November 2017 by Jane Williams
Therapeutic interventions have traditionally been developed for patients with established pathologies and overt clinical symptoms. Many diseases however, are not tractable in later stages and therefore therapies are needed that intervene earlier in the disease continuum.
Big data, knowing and AI: do they influence drug discovery?
Posted 8th November 2017 by Jane Williams
The quest for magic bullets started with Paul Ehrlich. He wanted to target the syphilis bacteria without harming the patients, which led to Salvarsan. Ehrlich was a foundational thinker, and we owe him modern concepts such as receptor and pharmacophore. His impact on the field – seeking the ideal molecules – pervades drug discovery.
Not Another IT System: Communities of Practice in Pharma
Posted 27th October 2017 by Jane Williams
Ever thought about how you avoid introducing “just another IT system”? How to get to the point where people work with the system joyfully and don’t mutter about the small faults or that no-one improves the system?
What’s Driving Change in Drug Discovery and Development?
Posted 16th October 2017 by Jane Williams
The past decade has witnessed huge advances in both scientific research and technological innovations within the drug discovery market. Here Dr James Willans, Chief Technology Officer of the not-for-profit organisation and educational charity, Lhasa Limited, discusses two significant areas that have the potential to further transform the industry over the coming years.
Network-Driven Drug Discovery – Circumventing the Limitations of Target-Driven Discovery
Posted 20th September 2017 by Jane Williams
Over the past five years, e-Therapeutics have created a drug discovery engine based on a combination of large-scale, proprietary databases and a suite of computational tools. Small molecules are evaluated by their potential bioactivity in the search for better and more effective drugs to address unmet medical needs. This article outlines the core principles and advantages of the Network-Driven Drug Discovery (NDD) approach.